Setterwalls advised Enzymatica AB (publ) in connection with a rights issue

Enzymatica AB (publ) develops and sells products that treat and relieve infections and symptoms in the upper respiratory tract. The products are based on Penzyme® technology, which includes marine enzymes with unique properties. The best-selling product is ColdZyme®, an oral spray for colds and cold-like symptoms in the upper respiratory tract. ColdZyme has been launched in roughly 30 markets on four continents. The company is headquartered in Lund and is listed on the Nasdaq First North Growth Market.